AIM: ) eradication rates using second-line bismuth-containing quadruple therapy and to identify predictors of eradication failure. METHODS: C-urea breath test or a rapid urease test at least 4 wk after the completion of bismuth-based quadruple therapy: proton pump inhibitor, metronidazole, bismuth, and tetracycline. RESULTS: eradication therapy failure. CONCLUSION: infection is still effective in Korea, and diabetes mellitus is suggested to be a risk factor for eradication failure.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: